Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
The serum concentration of the cell proliferation marker TPS (tissue polypeptide-specific antigen) was compared with the tumour marker PSA (prostate specific antigen). PSA was found elevated in 50% of the benign prostatic hypertrophy (BPH) patients, in 88% of the patients with active prostate cancer and in 40% of the patients who were in an inactive phase. For TPS these values were 6, 34 and 0%, respectively. The metastatic progression was biochemically mirrored by pronounced elevations of PSA and TPS. These data suggest that TPS might be a valuable adjunct in the diagnosis and follow-up of patients with prostate cancer, especially in differentiating benign from malignant deterioration of the disease.
Marrink
J
J
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
Oosterom
R
R
Bonfrer
H M
HM
Schröder
F H
FH
Mensink
H J
HJ
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D010455:Peptides / Q000097:blood*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D019396:Tissue Polypeptide Antigen
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D017430:Prostate-Specific Antigen